Quackwatch
Accueil » Ressources » Quackwatch » A Skeptical Look at Immuno-Augmentative Therapy (IAT)

A Skeptical Look at Immuno-Augmentative Therapy (IAT)

Stephen Barrett, M.D.

 

https://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/iat.html

 

 

https://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/iat.html

 

 

Références:

  1. Burton L Carcinogenic activity of larval donor abstracts in drosophila. Ph.D. dissertation, New York University, Feb 1955.
  2. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 270:1719-1723, 1993.
  3. Mitchell HK. Tumor inducing factor in Drosophila. Science 133:876, 1961.
  4. The Immunology Research Foundation, Inc. Information Bulletin Number 01b, undated, circulated in 1975.
  5. Burton L. Deposition in Louden vs. Prudential Insurance Co. of America, July 21, 1983, p. 7.
  6. Immu-augmentative therapy. FDA Talk Paper T82-14, March 2, 1982.
  7. Terry WD, Litvak J. Report to the Ministry of Health of Bahamas on the site visit to the Immunology Researching Centre, Limited, Jan. 29-31, 1978.
  8. Expenses. Immunology Research Centre Web site. Accessed several times during 1998 and 1999.
  9. The establishment vs. Dr. Burton. 60 Minutes, May 18, 1980.
  10. Bahamas Ca therapist drops U.S. research plan. Medical World News, Nov 24, 1980.
  11. Macconnell WP. Letter to Frank Rauscher, Jr. May 22, 1980.
  12. Barnes C. Testimony before the Subcommittee on Health and Long-Term Care of the U.S. House of Representatives Select Committee on Aging. In Pepper C and others. Quackery: A $10 Billion Scandal. Washington, D.C., 1984, U.S. Government Printing Office, 1984, pp. 37-39.
  13. Burton L. Deposition in Louden vs. Prudential Insurance Co. of America, July 21, 1983, pp. 10, 96-102.
  14. Gelband H and others. Immuno-Augmentative Therapy. In Gelband H and others. Unconventional Cancer Treatments. Washington, D.C.: U.S. Government Printing Office, 1990, pp 129-147.
  15. Questionable methods of cancer management: Immunoaugmentative therapy (IAT). CA—A Cancer Journal for Clinicians 41:357-363, 1991.
  16. Questions and answers for a non-technical orientation, pp. 1-2. In IAT (a looseleaf book distributed to the Florida legislature in April 1981).
  17. Immuno-augmentative Therapy. Undated brochure distributed in 1990.
  18. Zavertnik J. Immuno-augmentative therapy. In Barrett S, Cassileth BR (editors). Dubious Cancer Treatments. Tampa, FL: American Cancer Society, Florida Division, 1990.
  19. Letter from Bayard H. Morrison III, M.D., to Grace P. Monaco, June 7, 1984.
  20. Letter from Frank and Denise Wiewel to IAT patients, members and friends, July 13, 1987.
  21. Letter from MetPath board chairman Paul A. Brown, M.D., to Joseph J. Zavertnik, Oct 30, 1981.
  22. Burton L. Speech at meeting of the International Association of Cancer Victors and Friends, Ft. Lauderdale, FL, Feb 24, 1987.
  23. Letter from Walter W. Bond to Ronald St. John, M.D., July 5, 1985.
  24. Phillips T. Review and analysis of Lawrence Burton's patented processes and products. Contract report to OTA, Jan. 1989. Summarized in reference 14, above, pp 135-136.
  25. Curt GA, Katterhagen G, Mahaney F. Immunoaugmentative therapy. A primer on the perils of unproved treatments. JAMA 255:505-507, 1986.
  26. Nolen, WA. Dr. William Nolen challenges unorthodox healers. 50 Plus, November 1983, pp. 43-45, 70-71.
  27. Unpublished survey described in reference 14, above, pp 138-139.
  28. Cassileth BR and others. Report of a survival of patients receiving immunoaugmentative therapy, Sept. 1987.
  29. Information distributed to prospective patients in February 1989 by IAT-West included a letter from Curry Hutchinson, a copy of the Cassileth report, and a brochure: "About: Dr. Lawrence Burton and Immuno-Augmentative Therapy for Cancer."
  30. Diagnostic and Therapeutic Technology Assessment (DATTA): Immunoaugmentative therapy. JAMA 259:3477-3478, 1988.
  31. Pfeifer BL, Jonas WB. Clinical evaluation of "Immunoaugmentative Therapy (IAT)": An unconventional cancer treatment. Integrative Cancer Therapies 2:112-119, 2003.
  32. Immuno-Augmentative Therapy Case Histories. Undated, distributed in 1990.
  33. Sampson WI. Private communication to Dr. Stephen Barrett, January 1991.
  34. Centers for Disease Control: Cutaneous nocardiosis in cancer patients receiving immunotherapy injections - Bahamas. MMWR 33:471-477, 1984.
  35. Burton L. Testimony at Congressional hearing conducted by Congressman Guy V. Molinari, Jan. 15, 1986, transcript pp. 55-56.
  36. Curt GA. Warning on immunoaugmentative therapy. New England Journal of Medicine 311:859, 1984.
  37. Centers for Disease Control: Isolation of human T-lymphotropic virus type III/lymphadenopathy-associated virus from serum proteins given to cancer patients Bahamas. MMWR 34:490-491, 1985.
  38. St. John R. Report of trip to the Immunology Researching Centre on July 1-3, 1985.
  39. H.R. 7936, introduced Aug. 18, 1980, and H.R. 8341, introduced November 13, 1980.
  40. Wilson S. The rise and fall of Laetrile. Nutrition Forum 5:33­-40, 1988.
  41. Immu-augmentative therapy. Import alert #57-04, Aug 6, 1986.
  42. FDA issues import alert against dangerous cancer remedy. FDA Talk Paper T86-60, Aug. 7, 1986.
  43. Opinion. Odenwaller vs. Aetna Life Insurance Co., U.S. District Court for the Western District of Michigan. File No. K86-283CA4, May 27, 1988.
  44. Opinion of arbitrator. Odenwaller vs. Aetna Life Insurance Co, May 14, 1987, p. 11.
  45. Povtak T. Alternative cancer ttreatment clinic opening in Bahamas. Asbestos.com, Sept 5, 2-18.
  46. About us. Immune therapy.net, accessed Sept 12, 2018.

Dernière mise à jour le 9 mars 2019.

Source: Quackwatch Retour à la page d'accueil Partager

© 2019 Dr Stephen Barrett (version anglaise)
© 2019 Les Sceptiques du Québec (version française)